Background: Blood-brain equilibration rate constant (k e0 ) is derived from either pharmacokinetic and pharmacodynamic modeling (k e0_model ) or a model-independent observed time to peak effect (k e0_tpeak ). Performance in bispectral index (BIS) prediction was compared between k e0_model and k e0_tpeak for microemulsion or long chain triglyceride (LCT) propofol. Methods: Time to peak effect (t peak , time to a maximally reduced BIS value) of microemulsion propofol after an intravenous bolus (1 mg/kg) was measured in 100 patients (group A micro ). An observed t peak of 1.6 min for LCT propofol was obtained from an earlier study. Another 40 patients received a target controlled infusions of microemulsion propofol (k e0_model = 0.187/min, group B micro = 20) or LCT propofol (k e0_model = 0.26/min, group B LCT = 20) and remifentanil. The k e0_tpeak 's in group B micro and B LCT were calculated using the observed t peak value obtained from group A micro and 1.6 min, respectively. Effectsite concentrations of propofol were recalculated using the amounts of propofol infused over time and k e0_tpeak 's. Predicted BIS values calculated by sigmoid Emax equations with k e0_model and k e0_tpeak were compared with observed BIS values during induction and emergence for both formulations of propofol. Results: Observed t peak of microemulsion propofol was 1.68 min. The median performance errors of BIS in group B micro were -1.83% (-24.8 to 18.9, k e0_model ) and -2.42% (-26.1 to 36.2, k e0_tpeak ), while 8.01% (-20.5 to 30.1, k e0_model ) and 7.37% (-27.0 to 49.1, k e0_tpeak ) in group B LCT . The median absolute performance errors of BIS in group B micro were 11.87% (2.2-31.1k e0_model ) and 14.38% (-0.6 to 44.6, k e0_tpeak ), while 17.31% (5.54-36.0, k e0_model ) and 18.28% (-0.1 to 56.0, k e0_tpeak ) in group B LCT . Conclusions: The k e0_model showed better performance in BIS prediction than the k e0_tpeak . (Korean J Anesthesiol 2013; 65: 299-305) 
Introduction
Target-controlled infusion (TCI) systems were developed to administer intravenous agents during anesthesia. This is a logical approach for the fine titration of intravenous hypnotics and opioids and is based on the pharmacokinetic model that describes the disposition of the drug. For targeting effect-site concentrations, the TCI system should incorporate pharmacokinetic parameters, such as the distribution volume and clearance, and the blood-brain equilibration rate constant (k e0 ). Pharmacokinetic parameters can be determined by assessing the time course of the drug. On the other hand, k e0 can be estimated using pharmacokinetic/pharmacodynamic modeling of a single population (k e0_model ) or by calculating model-independent time-to-peak effects (k e0_tpeak ) [1, 2] . Although integrated pharmacokinetic/pharmacodynamic modeling of a single population is the standard method for obtaining k e0 , this is complicated by the need for blood samples and the frequent measurement of drug effects. As a result, the pharmacokinetic model for propofol that was reported by Marsh et al. [3] , a popular model used in clinical situations, only estimates pharmacokinetic parameters without k e0 .
The time of peak effect after bolus injection, t peak , could be used to link separate pharmacokinetic and pharmacodynamic studies [2] . The t peak method is based on the assumption that the time required to reach the maximal effect-site concentration is identical to the time required to produce the maximal drug effects. Minto et al. [2] reported that the t peak method, which is an alternative approach that can be used to obtain k e0 , can also be used to obtain better approximations of the postulated "true" time course of propofol effects in comparison with the naive method. The observed t peak of propofol was 1.6 minutes in a previous study [1] , which was then used to calculate k e0 using differential equations. The k e0 of long-chain triglyceride (LCT) propofol, which was calculated as 1.2152/min using the t peak method, is included the Orchestra workstation (Fresenius Kabi AG, Germany) and was previously modified by Marsh et al. [4] .
Microemulsion propofol (Aquafol; Daewon Pharmaceutical Co., Ltd, Seoul, Korea) was originally developed to overcome the drawbacks of LCT propofol [5] . Sequential pharmacokinetic/pharmacodynamic modeling of microemulsion propofol was performed in healthy volunteers [6] . The comparison of appropriateness between k e0 s derived from different methods in target effect-site concentration controlled infusion of propofol has yet to be fully elucidated. The aim of this study is to compare predictive performance in bispectral index (BIS, Aspect Medical Systems, Newton, MA, USA) prediction during target effect-site controlled infusion of propofol using different k e0 s in the same pharmacokinetic model.
Materials and Methods
Part 1: Patient population and study procedure used to determine the k e0 value of microemulsion propofol using the t peak method After obtaining approval from the Institutional Review Board of our institution and signed informed consent from all patients, a total of 100 patients diagnosed as American Society of Anesthesiologist (ASA) physical status (PS) 1 or 2 who were scheduled for stomach or colorectal surgery under general anesthesia were enrolled in this study. Patients with known or suspected cardiac, liver, or renal disease, significant obesity (> 120% of ideal weight), patients currently receiving sedative or analgesic drugs, and patients with known adverse effects to propofol were excluded. The patient characteristics are shown in Table 1 . All patients were required to fast starting the midnight before the operation without receiving premedication. Once in the operating room, patients were monitored using electrocardiography, pulse oximetry, end-tidal carbon dioxide partial pressure, noninvasive blood pressure monitoring (Datex-Ohmeda S/5; Planar Systems, Inc., Beaverton, USA), and BIS. Using RS232C cables, all data were continuously downloaded onto a personal computer until recovery from anaesthesia. An 18-gauge catheter was inserted into a large vein in the wrist. Forty milligrams of lidocaine were intravenously administered prior to propofol injection, then an intravenous bolus of 1 mg/kg microemulsion propofol was administered. After observing the maximal reduction in BIS from baseline, propofol and remifentanil were administered by effect-site target-controlled infusion (Asan Pump, version 2.1.3; Bionet Co., Ltd., Seoul, Korea). Part 2: Patient population and study procedure used to compare BIS predictions during TCI based on the 2 k e0 values determined in pharmacokinetic propofol models
A total of 40 ASA PS 1/2 patients who were scheduled for stomach, breast, or colorectal surgery were randomly divided and assigned to receive microemulsion (n = 20) or LCT propofol (n = 20; Pofol, Jeil Pharmaceutical Co., Ltd, Seoul, Korea). The patient characteristics are shown in Table 1 . All patients were required to fast starting the midnight before surgery without receiving any premedication. Once in the operating room, patients were monitored using electrocardiography, pulse oximetry, end-tidal carbon dioxide partial pressure, noninvasive blood pressure monitoring, and BIS. Using RS232C cables, these data were continuously downloaded onto a personal computer until recovery from anaesthesia. Each patient was preoxygenated with 100% oxygen via a facemask. Microemulsion propofol was administered via effect-site target-controlled infusion based on the Noh model, and a modified version of the Marsh model was used to administer LCT propofol to the other group of patients. The pharmacokinetic parameters and k e0 values of the Noh and modified Marsh models are shown in Table 2 [4, 6] . Remifentanil were administered via effect-site target-controlled infusion based on the Minto model [7] . Propofol and remifentanil were infused using TCI software, and the infusion histories of the patients were automatically recorded onto comma separated values (.csv) files. The pharmacokinetic parameters and k e0 values shown in Table 2 were programmed into the Asan pump. Tracheal intubation was facilitated by administering 0.12 mg/ kg vecuronium. Patients were then ventilated with a mixture of oxygen and air (delivered at a 1 : 2 ratio), and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35-45 mmHg. The target site-effective concentration of propofol was adjusted to maintain BIS values < 60. Target site-effective concentrations of remifentanil were titrated to maintain stable hemodynamics (i.e., systolic blood pressure [SBP] > 80 mmHg and heart rate [HR] > 45 beats/min). If necessary, ephedrine or atropine was administered to maintain SBP > 80 mmHg and HR > 45 beats/min during anesthesia. Neuro- The infusion history of propofol determined in Part 2 was used to simulate the effect-site concentration of propofol using different k e0 values in same pharmacokinetic model. In part 2, patients received microemulsion propofol using TCI with k e0 obtained by k e0_estimation method. On the other hand, patients received LCT propofol using TCI with k e0 obtained by k e0_tpeak method. For simulation, k e0 s of microemulsion and LCT propofol was changed to different k e0 s obtained by k e0_tpeak method for microemulsion propofol and k e0_estimation method for LCT propofol. k e0_estiation value for LCT propofol was obtained from the result of Billard et al. [8] . After each csv files was loaded in Asan Pump, k e0 s of propofol were changed to 0.26/min for LCT propofol and result of part 1 for microemulsion propofol [8] , and simulations of individual patients were performed by Asan Pump. Model summary for TCI and simulation of microemulsion and LCT propofol is shown in Table 3 .
Predictive performance
In accordance with a previous method [9] , the predictive performance of the TCI system was determined using the pharmacokinetic parameters and the k e0 values for each type of propofol were characterized based on 2 parameters: bias and inaccuracy. BIS values (measured from the induction of propofol infusion to intubation) and recovery periods (measured from the discontinuation of propofol infusion to extubation) were used to analyze the results of the present study. For each BIS value, the performance error (PE) of the ith patient was calculated as follows:
where predicted ij represents the predicted BIS value at the jth sampling point of the ith patient and measured ij is the observed BIS value.
The sampling interval (t j -t j-1 ) for BIS measurement was 10 seconds. The predicted value of BIS for each sample was calculated using the inhibitory sigmoid E max model:
where Effect is the BIS value, E 0 is the baseline BIS value when no drug is present, E max is the maximal possible drug effect on BIS, Ce is the predicted site-effective concentration of propofol determined in Part 3, Ce 50 is the site-effective concentration associated with 50% of the maximal drug effect on BIS, and γ is the steepness of the site-effective concentration vs the BIS relationship.
Various pharmacodynamic parameters for microemulsion and LCT propofol, such as E 0 , E max , Ce 50 , and γ, were determined in our previous studies [5, 6] . The first performance measure, the bias (i.e., the direction and size of deviation from the target) of the ith individual, was calculated as the median performance error (MDPEi) as follows:
The inaccuracy of BIS prediction (i.e., the size of the typical miss) of the ith individual was calculated as the median absolute performance error (MDAPE i ) as follows:
where N i is the number of blood sampling points for the ith individual. The pooled-data approach was used to obtain population estimates for bias and inaccuracy (fit4NM 3.5.1, Eun-Kyung Lee and Gyu-Jeong Noh, http://www.fit4nm.org/download, last accessed: Oct 17, 2011).
Statistical analysis
All statistical analyses were conducted using R software (version 2.13.1; R Foundation for Statistical Computing, Vienna, Austria) or SigmaStat 3.5 for Windows (Systat Software, Inc., Chicago, IL). Data are expressed as the mean ± standard deviation (SD) for normally distributed continuous variables, the LCT: long-chain triglyceride, k e0_estimation : estimated from sequential pharmacokinetic/pharmacodynamic modeling of a single population, k e0_tpeak : calculated using the observed time-to-peak effects.
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median (range: 25-75%) for nonnormally distributed continuous variables, and as counts and percentages for categorical variables. The relationship between age, time-to-peak effects, and BIS was analyzed using linear regression. All P values < 0.05 were considered statistically significant.
Results
All patients enrolled in the study of obtaining k e0 of microemulsion propofol calculated by t peak method were included in order to analyze the time to peak effect. Time course of BIS values after an intravenous bolus injection of microemulsion propofol 1 mg/kg are shown in Fig. 1. Median (25-75%) value of the time to maximally reduced BIS from baseline value was 1.68 (1.24-2.45) min. Also, relationship between age and time to peak effect in BIS are presented in Fig. 2 , where, with increasing age, time to peak effect (t peak ) increased.
A total of 1,027 BIS values (average value: 63.3 ± 16.9, sampling duration: 17.1 ± 3.5 min) from 20 patients receiving microemulsion propofol and 1,878 BIS values (average value: 59.3 ± 17.7, sampling duration: 24.0 ± 7.2 min) from 20 patients receiving LCT propofol were used to determine predictive performance in BIS prediction. Performance error (PE) and absolute performance error (APE) in BIS values for microemulsion propofol and LCT propofol according to the different k e0 s were depicted in Fig. 3 . PE of k e0_estimation was significantly lower than that of k e0_tpeak in microemulsion propofol (P = 0.013, Mann-Whitney rank sum test). APE of k e0_estimation showed significant differences in both formulations, compared with k e0_tpeak (P < 0.001, MannWhitney rank sum test). Bias (median performance error) and inaccuracy (absolute performance error) in BIS prediction values for microemulsion and LCT propofol in same pharmacokinetic model with different k e0 s are demonstrated in Table 4 . BIS values predicted by k e0_estimation method showed higher accuracy than those predicted by k e0_tpeak method.
Discussion
The median t peak of microemulsion propofol was 1.68 min. The k e0 derived from sequential pharmacokinetic and pharmacodynamic modeling showed higher accuracy in BIS prediction than that of k e0 calculated by the time to peak effect in both propofol formulations.
The t peak method should be used only for linking separate pharmacokinetic and pharmacodynamic studies for the same drug, as employed in an earlier study [1] , where t peak increased with age and this finding was consistent with our results. In other study [10] , t peak was not affected by age, which may be explained by the fact that distribution of age was relatively narrow (49 ± 16 yr). Age of patients enrolled in present study for obtaining k e0 of microemulsion propofol calculated by t peak method was 24-86 yr, which was similar to the previous study (25-81 yr) [1] . Overall, elderly patients showed prolonged onset of action on administration of drug [11, 12] . Age was a significant covariate for k e0 in population pharmacodynamic modeling of remifentanil, where t 2/1 k e0 increase with increasing age [7, 13] . These facts may be explain the relationship between age and time to peak effect, even though effect of age on k e0 of propofol using population pharmacodynamic analysis has not yet been elucidated.
In Noh model, lean body mass, weight and sex were significant covariates for V 2 , CL and Q 1 , respectively, resulting in different hybrid constants according to the individual patients. Hence, k e0 s of microemulsion propofol calculated by t peak method have different values when height, weight and sex are not identical LCT: long chain triglyceride, MDPE: median performance error, MDAPE: median absolute performance error, k e0_model : estimation from sequential phar macokinetic-pharmacodynamic modeling in a single population, k e0_tpeak : calculation using the observed time to peak effect. The value of k e0_model and k e0_ t peak for microemulsion propofol and LCT propofol were 0.19 /min and 1.68 min (time to peak effect) for microemulsion propofol and 0.26 /min and 1.21 /min for LCT propofol, respectively. Fig. 3 . Performance error and absolute performance error of the bispectral index (BIS) values for microemulsion propofol and long-chain (LCT) triglyceride propofol according to 2 k e0 s values. k e0_model : estimated from sequential pharmacokinetic/pharmacodynamic modeling of a single population, k e0_tpeak : calculated using the observed time-to-peak effects. The values of the k e0_model and k e0_tpeak models were 0.187/min and 1.68 min (time-to-peak effects) for microemulsion propofol and 0.26/min and 1.2152/min for LCT propofol, respectively. *P < 0.05 vs k e0_tpeak . Performance error (PE) was calculated as follows: In general, predictive performance of a TCI system was clinically acceptable when inaccuracy is less than 20-30 % [9] . Pharmacodynamic predictions as described by BIS exhibited smaller bias and inaccuracy in present study. Theoretically, because effect-site concentration per se should be statically related to effect, target effect-site controlled infusion using Noh or modified Marsh models can be available to predict BIS approximately, irrespective of method for obtaining k e0 .
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Biases and inaccuracies of a TCI system may be smallest when it incorporates pharmacokinetic parameters and k e0 obtained from a single population. Potential causes of performance errors in the predictive performance of a TCI system may include model misspecifications and mechanical errors of the infusion pump, such as trumpet curves [14] . A trumpet curve could be more likely to develop on long time of infusion. In this study, effect of trumpet curve can be excluded from interpretation of result, because predictive performance of BIS prediction was analyzed in induction and recovery periods.
Model misspecification of pharmacodynamic model shows a tendency of being smaller in the sequential pharmacokinetic and pharmacodynamic modeling, compared with simultaneous pharmacokinetic and pharmacodynamic modeling. Model misspecification of pharmacokinetic model can convert to that of pharmacodynamic model in simultaneous pharmacokinetic and pharmacodynamic modeling. Pharmacokinetics of microemulsion propofol were well described by mammillary three compartment model and the results of typical pharmacokinetic parameter were used to characterize the relationship concentration and effect using inhibitory sigmoid Emax model. In summary, the median time to maximally decreased BIS from baseline value after an intravenous bolus of microemulsion propofol 1 mg/kg was 1.68 min. BIS values predicted by k e0_estimation method showed higher accuracy than those predicted by k e0_tpeak method.
